Chemo-immunotherapy for hairy cell leukemia

Leukemia and Lymphoma

Volumn 52, Issue SUPPL. 2, 2011, Pages 72-74

  Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

cladribine; hairy cell leukemia; minimal residual disease; rituximab

Indexed keywords

CHLORAMBUCIL; CLADRIBINE; IMMUNOGLOBULIN G; IMMUNOTOXIN; IMMUNOTOXIN BL 22; PENTOSTATIN; RITUXIMAB; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CELLULITIS; CLINICAL TRIAL (TOPIC); CONSENSUS SEQUENCE; DRUG ERUPTION; DRUG FEVER; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FLOW CYTOMETRY; HAIRY CELL LEUKEMIA; HERPES ZOSTER; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOGLOBULIN VARIABLE REGION; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; NAUSEA; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDE EFFECT; SPLENECTOMY; SURVIVAL RATE; WEIGHT REDUCTION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; HUMANS; LEUKEMIA, HAIRY CELL; NEOPLASM, RESIDUAL; PENTOSTATIN;

EID: 79957449325     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.565096     Document Type: Article

References (16)

1. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21:891-896. (Pubitemid 46606450)
2. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995;13:974-982.
3. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009;145:733-740.
4. Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 2005;104:2442-2448. (Pubitemid 41691566)
5. Ravandi F, Jorgensen JL, O'Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006;107:4658-4662. (Pubitemid 43882611)
6. Wheaton S, Tallman MS, Hakimian D, Peterson L. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1996;87:1556-1560. (Pubitemid 26056921)
7. Sausville JE, Salloum RG, Sorbara L, et al. Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol 2003;119:213-217. (Pubitemid 37047876)
8. Sigal DS, Sharpe R, Burian C, Saven A. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 2010;115:1893-1896.
9. Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D. The natural history and clinico-pathological features of the variant formof hairy cell leukemia. Leukemia 2001;15:184-186. (Pubitemid 32124084)
10. Thomas DA, O'Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102: 3906-3911. (Pubitemid 37486969)
11. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003-4008. (Pubitemid 44920177)
12. Narat S, Gandla J, Dogan A, Mehta A. Successful treatment of hairy cell leukemia variant with rituximab. Leuk Lymphoma 2005;46:1229-1232. (Pubitemid 41087031)
13. Forconi F, Sozzi E, Cencini E, et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood 2009;114:4696-4702.
14. Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4- 34\+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009;114:4687-4695.
15. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabinewith concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101: 6-14. (Pubitemid 36025880)
16. Else M, Osuji N, Forconi F, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer 2007;110: 2240-2247. (Pubitemid 350100746)